<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754309</url>
  </required_header>
  <id_info>
    <org_study_id>KY1005-CT02</org_study_id>
    <secondary_id>2018-002299-41</secondary_id>
    <nct_id>NCT03754309</nct_id>
  </id_info>
  <brief_title>A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kymab Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kymab Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to investigate if KY1005 results in improvement of
      eczema when given to participants with moderate to severe disease. Side effects of KY1005
      will also be explored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy,
      safety and tolerability of two doses of KY1005 in adults with moderate to severe atopic
      dermatitis whose disease cannot be adequately controlled with topical medications or for whom
      topical treatment is medically inadvisable.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Actual">May 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Primary analysis up to day 113. Long term follow up to day 253 (dependent on response).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage and absolute change from Baseline in EASI over time</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in epidermal thickness</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in keratin 16 staining of skin biopsies</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 50% reduction in EASI (EASI 50)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 75% reduction in EASI (EASI 75)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 90% reduction in EASI (EASI 90)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Validated Investigator Global Assessment (vIGA)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a response of vIGA 0 or 1</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORing of Atopic Dermatis (SCORAD) Index</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in affected body surface area (BSA)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Orientated Eczema Measure (POEM)</measure>
    <time_frame>Baseline to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Orientated SCORing of Atopic Dermatitis (PO-SCORAD) Index</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Quality of Life Index (DLQI)</measure>
    <time_frame>Baseline to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Numerical Rating Scale (NRS) for pruritus</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>KY1005 lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose KY1005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KY1005 higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose KY1005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KY1005</intervention_name>
    <description>A human anti-OX40 ligand monoclonal antibody</description>
    <arm_group_label>KY1005 higher dose</arm_group_label>
    <arm_group_label>KY1005 lower dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (≥ 18 years but &lt; 75 years of age) with Atopic Dermatitis (AD) for 1 year or
             longer at Baseline (Day 1; prior to first administration of Investigational Medicinal
             Product (IMP)).

          -  EASI of 12 or higher at the Screening Visit and 16 or higher at Baseline.

          -  vIGA of 3 or 4 at Baseline.

          -  AD involvement of 10 percent or more of BSA at Baseline.

          -  Documented history, within 6 months prior to Baseline, of either inadequate response
             to topical treatments or inadvisability of topical treatments.

          -  Must have applied a stable dose of topical bland emollient (simple moisturiser, no
             additives [e.g., urea]) at least twice daily for at least 7 consecutive days before
             Baseline.

          -  Able and willing to comply with requested study visits/telephone visits and
             procedures.

          -  Able and willing to provide punch biopsy of both lesional and non-lesional skin at
             Baseline.

          -  Able and willing to provide written informed consent.

        Exclusion Criteria:

          -  Recent treatment within specific time windows before the baseline visit for the
             management of atopic dermatitis such as topical or systemic corticosteroids, biologic
             or investigational therapies and/or phototherapy.

          -  Known history of or suspected significant current immunosuppression, including history
             of invasive opportunistic infections despite infection resolution or otherwise
             recurrent infections of abnormal frequency or prolonged duration.

          -  Basal and squamous cell skin cancer in the last 3 years prior to Baseline. Any other
             malignancies in the last 5 years prior to Baseline (excluding in situ cervical
             carcinoma).

          -  Severe concomitant illness that would in the Investigator's opinion inhibit the
             patient's participation in the study, including for example, but not limited to, renal
             disease, neurological conditions, heart failure and pulmonary disease.

          -  Laboratory values at the Screening Visit:

          -  a. Serum creatinine &gt; 1.6 mg/dL (141 μmol/L) in female patients and &gt; 1.9 mg/dL (168
             μmol/L) in male patients;

          -  b. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 1.5 × upper
             limit of normal (ULN);

          -  c. Platelet count &lt; 100 × 10^9/L;

          -  d. Haemoglobin (Hb): Male &lt; 13.5g/dL and Female &lt;12g/dL;

          -  e. White blood cell count (WBCC) &lt; 3.0 × 10^9/L;

          -  f. Absolute neutrophil count &lt; 2.0 × 10^9/L;

          -  g. Absolute lymphocyte count &lt; 0.5 × 10^9/L;

          -  h. Total bilirubin &gt; ULN.

          -  Participation in any other clinical study, including non-interventional studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Weidinger, MaHM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein, 24105 Kiel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kymab investigational site 106</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 113</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 207</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 216</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 206</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 212</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 213</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 214</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 203</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 210</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigator site 201</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 204</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 202</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 304</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 303</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 302</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 315</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 420</name>
      <address>
        <city>Harrogate</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 402</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

